In line with the expression of BCMA on PBs and PCs, BCMA is highly expressed on multiple myeloma cells, and is considered a validated target, based on approval of the BCMA-targeted therapies belantamab mafodotin and idecabtagene vicleucel, for treatment of advanced multiple myeloma (17–19). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.